Semaglutide oral (obesity)
WEGOVY (oral)
Pronunciation: sem-a-GLOO-tide
“(Rebel, Olympic, & Wig governor) See my glue tide”
Glasses on the mascots → “see my glue tide”
Rebel saying “You ain’t injectin’ me!” → Rybelsus is oral, unlike Ozempic/Wegovy
What it isOral GLP-1 receptor agonist formulation for chronic weight management in obesity.
Why this oneIt was the first oral GLP-1 approved for weight management, preserving a familiar molecule without injections.
What limits itAbsorption is fragile: take alone on an empty stomach exactly as directed. GI intolerance and delayed gastric emptying still matter.
Semaglutide oral (obesity) prescription history
Animated chart of estimated U.S. prescriptions per year, Obesity meds (1959–2026). Semaglutide oral (obesity) enters in 2018 (estimated).
Classes and tags
Clinical profile
Legacy pregnancy categoryNot assigned — PLLR-era drug
Defining liabilityGI intolerance, gallbladder disease and rare pancreatitis; hypoglycemia is uncommon without insulin or sulfonylureas.
FDA label
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Reduce risk of major adverse CV events (established CV disease with obesity or overweight) | Adults | 1.5 mg QD × 30 days | 25 mg QD | 25 mg QD |
| Chronic weight management (obesity, or overweight with ≥1 weight-related comorbidity), with reduced-calorie diet and increased activity | Adults | 1.5 mg QD × 30 days | 25 mg QD | 25 mg QD |
Titration Escalate every 30 days: 1.5 mg (days 1–30) → 4 mg (31–60) → 9 mg (61–90) → 25 mg (91+); delay escalation if not tolerated.
Renal No dosage adjustment needed (eGFR ≥30 to <90 mL/min studied); monitor renal function with volume-depleting GI reactions.
Hepatic No dosage adjustment needed (mild–severe hepatic impairment, Child-Pugh A–C, studied).
If the 25 mg maintenance tablet is not tolerated, consider switching to Wegovy injection 1.7 mg once weekly.
Instructions
- Take once daily on an empty stomach in the morning with up to 4 oz (120 mL) plain water only — no other liquids
- Swallow tablet whole; do not split, crush, chew, or dissolve
- Wait at least 30 minutes before eating, drinking, or taking other oral medications
- Do not take more than one tablet per day; if a dose is missed, skip it and take the next dose the following day
- Use with a reduced-calorie diet and increased physical activity
- If 25 mg once daily is not tolerated, consider switching to Wegovy 1.7 mg injection once weekly
Available strengths
- tab 1.5, 4, 9, 25 mg
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Prior serious hypersensitivity reaction to semaglutide (anaphylaxis and angioedema reported)
Cautions
- Acute pancreatitis — discontinue if suspected
- Acute gallbladder disease (cholelithiasis, cholecystitis)
- Hypoglycemia when used with insulin or an insulin secretagogue — consider reducing their dose
- Acute kidney injury due to volume depletion — monitor renal function
- Severe gastrointestinal reactions — not recommended in severe gastroparesis
- Hypersensitivity reactions (anaphylaxis, angioedema) — discontinue if suspected
- Diabetic retinopathy complications in patients with type 2 diabetes
- Heart rate increase — monitor
- Pulmonary aspiration during general anesthesia or deep sedation (delayed gastric emptying)
Adverse reactions
- Nausea, diarrhea, vomiting, constipation, abdominal pain, abdominal distension, eructation, flatulence, dyspepsia, GERD, gastroenteritis
- Headache, fatigue, dizziness, dysesthesia
- Hypoglycemia in patients with type 2 diabetes
- Hair loss
Pregnancy May cause fetal harm; discontinue when pregnancy is recognized (for CV risk reduction or weight reduction). Discontinue at least 2 months before a planned pregnancy (long half-life).
Lactation Breastfeeding not recommended during treatment with Wegovy tablets (potential SNAC accumulation in the infant).
Cost
| Strength | #/mo | generic $/mo | brand $/mo | CostPlus | |
|---|---|---|---|---|---|
| 1.5 mg | tab | 30 qd | — | $1,149.68 | not offered |
| 4 mg | tab | 30 qd | — | $1,149.99 | not offered |
| 9 mg | tab | 30 qd | — | $1,149.66 | not offered |
| 25 mg | tab | 30 qd | — | $1,302.87 | not offered |
Other forms: Semaglutide (OZEMPIC, WEGOVY) · Semaglutide oral (RYBELSUS) · Semaglutide (obesity) (WEGOVY)
Open Semaglutide oral (obesity) in the interactive console ↗
Memory aids: interaction avatars
Open Semaglutide oral (obesity) in the interactive console ↗
Self-check
- What administration advantage does oral Wegovy offer?
Weight management without injections. - How should oral Wegovy be taken?
Alone on an empty stomach, exactly as directed.